Metastatic Prostate Cancer

Oncology
9
Pipeline Programs
10
Companies
7
Clinical Trials
2 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
2
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 7 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
ABIRATERONE ACETATEApproved
abiraterone acetate
Unknown Company
oral2019

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
2 programs
1
1
abiraterone acetatePhase 3
TazemetostatPhase 1/2Small Molecule1 trial
Active Trials
NCT04179864Terminated102Est. Nov 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD0754Phase 1/21 trial
Active Trials
NCT06267729Recruiting60Est. Nov 2026
Providence Therapeutics
1 program
1
Anti-OX40Phase 11 trial
Active Trials
NCT01303705CompletedEst. Jul 2016
Sanofi
SanofiPARIS, France
1 program
1
PACE with CabazitaxelPhase 1
Astellas
AstellasChina - Shenyang
1 program
1
PACE with CabazitaxelPhase 11 trial
Active Trials
NCT03110588Withdrawn0Est. Dec 2019
M&
Merck & Co.RAHWAY, NJ
1 program
1
[¹⁴C]OpevesostatPhase 1Small Molecule1 trial
Active Trials
NCT06566989Completed8Est. Oct 2024
Blue Earth Therapeutics
1 program
1
lutetiumPhase 11 trial
Active Trials
NCT06516510TerminatedEst. Aug 2025
Novartis
NovartisBASEL, Switzerland
1 program
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)N/A1 trial
Active Trials
NCT07290270Recruiting170Est. Aug 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
AstraZenecaAZD0754
IpsenTazemetostat
Blue Earth Therapeuticslutetium
Merck & Co.[¹⁴C]Opevesostat
AstellasPACE with Cabazitaxel
Providence TherapeuticsAnti-OX40
NovartisReal-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Clinical Trials (7)

Total enrollment: 340 patients across 7 trials

NCT06267729AstraZenecaAZD0754

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Start: Mar 2024Est. completion: Nov 202660 patients
Phase 1/2Recruiting
NCT04179864IpsenTazemetostat

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Start: Nov 2019Est. completion: Nov 2024102 patients
Phase 1/2Terminated
NCT06516510Blue Earth Therapeuticslutetium

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

Start: Oct 2024Est. completion: Aug 2025
Phase 1Terminated
NCT06566989Merck & Co.[¹⁴C]Opevesostat

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Start: Sep 2024Est. completion: Oct 20248 patients
Phase 1Completed
NCT03110588AstellasPACE with Cabazitaxel

Phase I Trial of PACE for Metastatic Prostate Cancer

Start: May 2018Est. completion: Dec 20190
Phase 1Withdrawn
NCT01303705Providence TherapeuticsAnti-OX40

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Start: Oct 2010Est. completion: Jul 2016
Phase 1Completed
NCT07290270NovartisReal-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

Start: Feb 2026Est. completion: Aug 2029170 patients
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
2h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
2h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 340 patients
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)